Legend Biotech Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This Legend Biotech Value Chain Analysis helps you understand how the company creates value through its support and primary activities in one clear framework. The page already shows a real preview of the analysis, so you can review the content and style before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Legend Biotech's firm infrastructure must coordinate research, quality, regulatory, and commercial teams across a global cell therapy platform. CAR-T work needs tight control from process development through post-launch safety monitoring, so governance and data flow are central to execution. This structure supports scale-up of CARVYKTI and the quality systems needed for a complex, patient-specific product.
Human Resource Management
Legend Biotech's Human Resource Management is built around scientists, clinical operators, quality specialists, and manufacturing staff with cell therapy know-how. Retention matters because CAR-T work is patient-specific and regulated, and one batch can take weeks of controlled processing and release checks. In 2025, Legend Biotech reported $1.14 billion in revenue, so keeping scarce talent in place directly supports output, quality, and supply.
Technology Development
Legend Biotech's technology development is anchored in CAR-T science, process control, and pipeline work that keeps CARVYKTI moving beyond a one-product story. By 2025, CARVYKTI had 2 U.S. FDA-approved indications, showing how steady R&D can improve targeting, manufacturing consistency, and label expansion into earlier-line multiple myeloma care.
Procurement
Legend Biotech's procurement must lock down viral vectors, cell culture inputs, single-use systems, and cold-chain materials to exact specs, because even small supplier swings can hit CAR-T quality and yield. In 2025, that buying discipline matters more as CARVYKTI scale-up keeps pressure on batch reliability, supply continuity, and cost control in a complex autologous model.
Support Systems Power Legend Biotech's CARVYKTI Scale
Legend Biotech's support activities in 2025 were built to keep CARVYKTI compliant, supplied, and scaled. Its infrastructure, talent, R&D, and procurement all serve a regulated CAR-T model that depends on tight quality control and cold-chain discipline. With $1.14 billion in 2025 revenue and 2 U.S. FDA-approved CARVYKTI indications, the support base clearly backed growth.
| 2025 metric | Value |
|---|---|
| Revenue | $1.14B |
| CARVYKTI U.S. FDA indications | 2 |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Legend Biotech's inbound logistics starts with 1 patient leukapheresis collection, then moves into raw materials for engineered cell production. Because each batch is tied to one patient and one treatment slot, chain-of-identity checks and cold-chain timing are critical. In 2025, that same patient-specific flow supported CARVYKTI demand, with supply speed and batch accuracy directly affecting revenue and slot utilization.
Operations
Operations turns a patient's collected cells into CARVYKTI through engineering, expansion, testing, and final release. In 2025, this step stayed the main value driver because CAR-T lots must pass strict identity, potency, sterility, and release checks before infusion. Faster cycle time and higher manufacturing yield matter: they lift supply for a therapy used in relapsed or refractory multiple myeloma after at least one prior line.
Outbound Logistics
Legend Biotech's outbound logistics keep finished doses cryopreserved, tracked, and delivered to qualified treatment centers for infusion. This is critical for CARVYKTI, a one-patient, one-dose therapy, where temperature control and timing protect product quality. In 2025, disciplined cold-chain delivery remained a core step between manufacturing release and patient treatment.
Marketing and Sales
Legend Biotech sells CARVYKTI through a hematology-first model, with Janssen handling key commercialization work in myeloma centers. In 2025, the focus stayed on finding eligible patients, training physicians, and speeding access beyond late-line use. That sales motion supports broader adoption as CARVYKTI moves into earlier treatment settings and uses a specialist call plan, not a broad sales force.
Service
Legend Biotech's service work centers on treatment-center onboarding, ordering support, REMS coordination, and post-infusion follow-up, which matters in CAR-T because hospitals need tight process control. Strong service lowers admin friction, helps keep centers compliant, and supports repeat use of the therapy. That can also protect patient access after infusion, where delays or errors can hit utilization fast.
CARVYKTI Logistics: Speed, Precision, and Tight Chain-of-Identity Control
Legend Biotech's primary activities are built around CARVYKTI, a one-patient, one-dose CAR-T therapy, so inbound, operations, and outbound logistics all depend on tight chain-of-identity control. In 2025, faster release and fewer batch errors mattered most because each slot ties to one patient and one infusion.
| Activity | 2025 focus |
|---|---|
| Operations | Engineering, testing, release |
| Outbound | Cryogenic delivery to centers |
Sales and service stayed centered on hematology centers, REMS support, and treatment-site onboarding, which helps speed access and protect utilization.
What You See Is What You Get
Legend Biotech Reference Sources
This is the actual Legend Biotech Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see is exactly what you get. Unlock the complete, detailed version immediately after checkout.
Frequently Asked Questions
CARVYKTI drives Legend Biotech's value chain most. The therapy moved from a 2022 late-line FDA label to a 2024 earlier-line indication, expanding the addressable market from 4 prior lines to 1 prior line in the U.S. That change makes manufacturing throughput, treatment-center activation, and partner-supported commercialization the most important value drivers.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.